Pharmaceuticals, Biotechnology and Life Sciences
The revenue decline reflects the following impact of the previously announced Natest SNDS and Estrace shortage in the Canadian market, Acerus said.
Acerus Pharmaceuticals said Thursday in a press release that new data showed that Natesto increases serum testosterone and improves symptoms…
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter from SWK related to certain financial covenants for Q3 2019.
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million…
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC
Acerus posts total revenues in Q1-2019 of $2.2 million, an increase of $0.5 millionor 33% compared to the first quarter of 2018 (“Q1-2018”).